ArticleEuropean heart journal open2026
Permanent LEft ventricular septAl Pacing vs. right ventricular pacing in patients with atrioventricular conduction disorders-a randomized trial: rationale and design of the LEAP trial.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Permanent cardiac pacing is the only available therapy in patients with atrioventricular (AV) conduction disorders and can be lifesaving. However, conventional right ventricular pacing (RVP) causes dyssynchronous electrical and mechanical activation of the ventricles, possibly resulting in pacing-induced cardiomyopathy and heart failure. Left bundle branch area pacing (LBBAP) might overcome these adverse effects of RVP, but evidence to support this assumption is lacking. The LEAP trial is a multi-centre investigator-initiated, prospective, randomized controlled, open-label, blinded endpoint evaluation (PROBE) study, designed to test the hypothesis that in patients with an indication for pacemaker implantation due to AV conduction disorders with an expected ventricular pacing percentage ≥20%. LBBAP is superior to RVP in preventing the composite primary endpoint of (1) all-cause mortality, (2) hospitalization for heart failure, and (3) a more than 10% point decrease in left ventricular ejection fraction (LVEF) leading to an LVEF below 50%. The LEAP trial randomizes 470 patients 1:1 to the index LBBAP or RVP control arm. The primary endpoint will be determined at 1-year follow-up. This article describes the design and analytic plan for the trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.